Advanced Accelerator Applications Launches “Hope Is Like Air” Campaign in support of NET Cancer Day
Zebra Striped Pinwheels Displayed on November 10 to Raise Awareness of Neuroendocrine Tumors
Advanced Accelerator Applications S.A. (AAA), a Novartis company and leader in nuclear medicine theragnostics, in collaboration with Neuroendocrine Tumor (NET) patient organizations around the world, is launching an international campaign, “Hope Is Like Air”, to raise awareness of NET Cancer Day on November 10. The global initiative, which will involve thousands of zebra-striped pinwheels adorning green spaces and special events in the US and Europe, aims to shed light on this rare, often undiagnosed or misdiagnosed, form of cancer.
NET patient advocacy groups participating in the Hope Is Like Air pinwheel project include Capital Area Carcinoid Survivors Group (CACS), Carcinoid Cancer Foundation, Healing NET Foundation, Los Angeles Carcinoid Neuroendocrine Tumor Society (LACNETS), Neuroendocrine Cancer Awareness Network (NCAN), Neuroendocrine Tumor (NET) Research Foundation, Northern California CarciNET Community (NorCal), and San Diego Orange County Carcinoid NETs in the US; as well as NET Patient Foundation in the UK, APTED of France, A.I.NET Italy, NET Italy, and two groups in Poland - Association of Patients and Supporters of Neuroendocrine Tumors, and Foundation for Endocrinology and Oncological Endocrinology (Pro Endocrinology) of Krakow.
“Due to the rare nature of NETs, and the broad range of symptoms that may or may not be expressed by individuals with the disease, patients may go years without receiving an accurate diagnosis,” said Susanne Schaffert, Ph.D., President of Advanced Accelerator Applications. “These delays often leave patients feeling isolated and in search of hope, which can be as essential to survival, as the air we breathe. Our goal is to raise awareness of NETs in communities around the world and generate a breath of hope for patients and their loved ones.”
Zebra stripes are the symbol of neuroendocrine tumors, meant to signify the individuality of each patient and their disease, as well as encourage medical professionals to consider diagnoses beyond the most common ones. As the disease is rare and often overlooked, the neuroendocrine tumor community encourages healthcare providers to metaphorically consider the rare and unexpected possibility of a zebra, not a common horse, when they hear hoofbeats.
About Neuroendocrine Tumors1
Neuroendocrine tumors, or NETs, are a rare type of cancer that originate in neuroendocrine cells throughout the body. They are most often found in the gastrointestinal tract, lungs or pancreas. Each year 6.98 out of every 100,000 people are diagnosed with NETs2. NETs can be defined as functional or nonfunctional. Functional NETs are characterized by symptoms caused by the over-secretion of hormones and other substances, while nonfunctional NETs may be clinically silent.
Symptoms often appear once the tumor produces hormones or grows into surrounding tissues and organs. Non-specific signs and symptoms of NETs include, but are not limited to, abdominal pain, asthma-like wheezing, diarrhea, fatigue, flushing, nausea, weight loss, and unusual bleeding.
NETs tend to grow slowly and can have no symptoms or vague symptoms that can be mistaken for other conditions. As a result, NETs are often diagnosed at an advanced stage, meaning the cancer cells have already spread to other parts of the body.
This statement contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this statement, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this statement will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political and economic conditions; safety, quality or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this statement as of this date and does not undertake any obligation to update any forward-looking statements contained in this statement as a result of new information, future events or otherwise.
About Advanced Accelerator Applications S.A.
Advanced Accelerator Applications, a Novartis company, is an innovative radiopharmaceutical company developing, producing and commercializing radioligand theragnostics. AAA is an established leader in radiopharmaceuticals for Positron Emission tomography (PET) and Single-Photon Emission Computed Tomography (SPECT) diagnostic imaging, mainly used in clinical oncology, cardiology and neurology. For more information, please visit: https://www.adacap.com/.
2 Dasari A, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017; 3(10):1335-1342.
Advanced Accelerator Applications
+1 212 235 2395 (direct)
+1 917 375 2935 (mobile)
Participating Patient Group WebsitesCapital Area Carcinoid Survivors
Carcinoid Cancer Foundation
Healing NET Foundation
NET Research Foundation
San Diego Orange County Carcinoid NETs
A.I. NET Italy
NET Patient Foundation UK
Association of Patients and Supporters of Neuroendocrine Tumors Poland